| Quantity | 1 mg, 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg, 10 mg | 10 µ, g, 50 µ, g, 100 µ, g | 1 mg, 5 mg, 10 mg | 1 mg, 5 mg, 10 mg |
| Description | OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research[1]... Read More | Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor | Luteinizing hormone (human), a heterodimeric glycoprotein hormone produced by the pituitary gland (LH), plays key roles in human reproduction[1] | Mastoparan, a tetradecapeptide which is a component of wasp venom, stimulates release of prolactin from cultured rat anterior pituitary cells | Neuropeptide W-23 (human) (NPW-23), the active form of Neuropeptide W, is an endogenous agonist of NPBW1 (GPR7) and NPBW2 (GPR8)[1] |